S

Sanofi

Global pharma company; vaccines and R&D

Zone Development Manager Hematology

Full-TimeDeadline 11/30/26
$113.3k - $188.8k+ Annual bonus eligibility + Company car
Mid
Bachelor's, MBA
Cambridge, MA, USA+1 moreMore locations: Denver, CO, USA
HybridApproximately 40% travel is expected. Must reside in the West or Central region, or the Boston/Cambridge, MA area.
Business & StrategyBusiness Operations

About the job

Requirements
  • A bachelor's degree (BA/BS) is required; life sciences or business is preferred, and an MBA is a plus.
  • At least 4 years of industry experience in pharmaceutical, biotech, or medical device roles such as sales, commercial operations, marketing, training, or project management.
  • Ability to learn and apply technical and scientific product information.
  • Ability to travel to meetings, trainings, and programs as required; approximately 40% travel is expected.
  • Valid driver's license.
  • Must reside within the West or Central region, or in the Boston/Cambridge, Massachusetts area.
Responsibilities
  • Support two Divisional General Managers (West and Central) and a combined field team of Regional Business Directors, Account Business Managers, Key Account Managers, and Thought Leader Liaisons.
  • Create agendas for divisional meetings, execute timely follow-up, and assign actionable items with clear accountability to appropriate stakeholders.
  • Coordinate promotional programming, congress activities, and budget allocation to maximize business impact.
  • Train field teams on business tools and systems, including Veeva and analytics platforms, and pilot new initiatives before broader rollout.
  • Implement and scale account-planning initiatives across the division to optimize customer engagement.
  • Participate in key workstreams, including SFAST, marketing partnerships, and special projects, to ensure the field voice is represented in home-office decisions.
  • Track and analyze performance metrics across account, divisional, regional, and territory levels to generate actionable insights for strategic decision-making.
  • Conduct sales and gap analyses to assess sales strategy effectiveness and recommend solutions to improve sales performance.
  • Provide national, divisional, regional, and territory-level analysis to identify opportunities to optimize performance.
  • Evaluate current analytics tools with the Divisional General Manager and provide ongoing input for improvement.
  • Share analytics best practices across the division and nation in collaboration with the Divisional General Manager.
  • Collaborate with training and field teams to develop comprehensive POAs aligned with organizational goals.
  • Support planning and successful execution of POA meetings with the POA Planning Group.
  • Participate in field working groups, including SFAST, IC, Cross-Functional Teams, Data Champs, and Culture Team initiatives.
  • Support New Hire Training programs and ABM field training initiatives.
Desired Qualifications
  • Oncology commercial experience is strongly preferred.
  • Experience in field-based training, project management, commercial operations, sales, sales leadership, or marketing.
  • A proven track record as a high-level performer with demonstrated readiness for expanded responsibility.
  • Strong business acumen and the ability to develop and execute business plans that achieve commercial goals.
  • Verbal and written communication skills, including executive-level presentation ability.
  • Cross-functional collaboration skills and the ability to influence without authority.
  • Formal or informal leadership experience.
  • Career aspirations toward home-office leadership, field management, or senior commercial roles.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...